ABSTRACT
The epidemiology of seasonal influenza is influenced by age. During the influenza season, the European Influenza Surveillance Network (EISN) reports weekly virological and syndromic surveillance data [mostly influenza-like illness (ILI)] based on national networks of sentinel primary-care providers. Aggregated numbers by age group are available for ILI, but not linked to the virological data. At the end of the influenza season 2012/2013, all EISN laboratories were invited to submit a subset of their virological data for this season, including information on age. The analysis by age group suggests that the overall distribution of circulating (sub)types may mask substantial differences between age groups. Thus, in cases aged 5-14 years, 75% tested positive for influenza B virus whereas all other age groups had an even distribution of influenza A and B viruses. This means that the intepretation of syndromic surveillance data without age group-specific virological data may be misleading. Surveillance at the European level would benefit from the reporting of age-specific influenza data.
Subject(s)
Influenza, Human/epidemiology , Influenza, Human/virology , Orthomyxoviridae/classification , Orthomyxoviridae/isolation & purification , Adolescent , Adult , Age Factors , Aged , Aged, 80 and over , Child , Child, Preschool , Europe/epidemiology , Female , Humans , Infant , Infant, Newborn , Male , Middle Aged , Young AdultABSTRACT
This paper summarizes influenza activity in the European Union/European Economic Area (EU/EEA) in 2012-2013. The influenza season 2012-2013 in Europe lasted from early December to late April. Overall the severity of the season could be described as moderate, based on the ILI/ARI consultation rates and the percentage of sentinel specimens positive for influenza compared to previous seasons. Both influenza A and B viruses circulating accounted for 47% and 53% of positive sentinel specimens, respectively, with both A(H1) and A(H3) varying for dominance. Compared to outpatients, the proportion of laboratory-confirmed influenza hospitalized cases infected by A(H1N1)pdm09 was significantly higher in middle-aged patients (33% vs. 17%, χ 2 = 66·6, P < 0·01). Despite a relatively good match between vaccine and circulating strains, vaccine effectiveness was estimated to be moderate.
Subject(s)
Influenza A virus/isolation & purification , Influenza B virus/isolation & purification , Influenza, Human/epidemiology , Europe/epidemiology , Humans , Influenza, Human/virologyABSTRACT
A rapid survey by the European Centre for Disease Prevention and Control (ECDC) and the World Health Organization (WHO) Regional Office for Europe ascertained the availability of national reference laboratory testing for a recently detected novel coronavirus as of 28 November 2012. Screening by internal quality controlled upE-RT-PCR assay was available in 23/46 of responding countries in the WHO European Region, of which 19/30 in European Union (EU) and European Economic Area (EEA) countries. Confirmation of positive screened samples by either ORF1b - RT-PCR, or other target RT-PCR assays with sequence analysis or whole-genome sequence analysis was available in 22/46 responding countries of which 18/30 in EU/EEA countries.
Subject(s)
Coronavirus Infections/diagnosis , Coronavirus/isolation & purification , Laboratories/standards , Reverse Transcriptase Polymerase Chain Reaction/methods , Coronavirus/genetics , Coronavirus Infections/genetics , Coronavirus Infections/virology , European Union , Humans , RNA, Viral/genetics , Reference Standards , Sequence Analysis , World Health OrganizationABSTRACT
In France, Ireland, Spain and the United Kingdom, the influenza season 2011/12 started in the final weeks of 2011 and has been dominated by influenza A(H3) viruses with minimal circulation of influenza A(H1N1) pdm09 and B viruses. A relatively greater proportion, however, of influenza A(H1N1)pdm09 viruses were reported in hospitalised laboratory-confirmed influenza cases in four countries. Compared to the season 2010/11, the proportion of subtype A(H3) among hospitalised cases has increased, associated with a larger proportion of cases in the youngest and oldest age groups.
Subject(s)
Influenza A Virus, H1N1 Subtype/isolation & purification , Influenza, Human/epidemiology , Seasons , Severity of Illness Index , Adolescent , Adult , Aged , Child , Child, Preschool , Female , France/epidemiology , Humans , Influenza, Human/diagnosis , Ireland/epidemiology , Male , Middle Aged , Population Surveillance/methods , Spain/epidemiology , United Kingdom/epidemiology , Young AdultABSTRACT
The 2011 influenza season (May to October) in the southern hemisphere was dominated by the A(H1N1) viruses that emerged during the 2009 influenza A(H1N1) pandemic and influenza B viruses, although the proportion of these two varied between and within countries. Some influenza A(H3N2) viruses were also seen. We discuss here the preliminary implications for Europe of the 2011 influenza season in five temperate southern hemisphere countries.
Subject(s)
Influenza, Human/epidemiology , Europe/epidemiology , Global Health , Humans , Influenza A Virus, H1N1 Subtype , Influenza Vaccines , Influenza, Human/prevention & control , SeasonsABSTRACT
BACKGROUND: Signaling through the leukemia inhibitory factor (LIF) receptor (LIFR) is crucial for nervous system development. There are few studies concerning the expression of LIF and LIFR in normal and degenerating adult human brain. OBJECTIVES: To study the expression of LIF and LIFR in Alzheimer's disease (AD), Parkinson's disease (PD), and control brains. PATIENTS AND METHODS: LIF and LIFR mRNA copy numbers were determined by quantitative real-time RT-PCR from four brain regions of 34 patients with AD, 40 patients with PD, and 40 controls. Immunohistochemistry was performed in seven PD and in four AD patients and in seven normal controls. RESULTS: In general, the LIF copy numbers were 1 log higher than the LIFR copy numbers. In the AD brains, LIF expression was higher than in the controls in the hippocampus and in the temporal cortex, and in the PD brains in the hippocampus and in the anterior cingulated cortex. Expressions of LIF and LIFR in different brain regions were opposite except for the AD hippocampus and PD anterior cingulated cortex, where the expression patterns were parallel. CONCLUSIONS: Co-operative expression of LIF and LIFR in AD hippocampus and PD anterior cingulated cortex may indicate a role for LIF in neuronal damage or repair in these sites.
Subject(s)
Alzheimer Disease/genetics , Alzheimer Disease/pathology , Brain/pathology , Leukemia Inhibitory Factor/genetics , Parkinson Disease/genetics , Parkinson Disease/pathology , Receptors, OSM-LIF/genetics , Aged , DNA Primers/genetics , DNA, Complementary/genetics , Disease Progression , Female , Gyrus Cinguli/pathology , Hippocampus/pathology , Humans , Immunohistochemistry , Male , Reverse Transcriptase Polymerase Chain ReactionSubject(s)
Disease Outbreaks/statistics & numerical data , Influenza A Virus, H3N2 Subtype/genetics , Influenza, Human/epidemiology , Seasons , Sentinel Surveillance , Adolescent , Adult , Aged , Child , Child, Preschool , Europe/epidemiology , Hospitalization/statistics & numerical data , Humans , Infant , Influenza A Virus, H1N1 Subtype , Influenza A Virus, H3N2 Subtype/classification , Influenza A Virus, H3N2 Subtype/isolation & purification , Influenza B virus , Influenza, Human/diagnosis , Influenza, Human/virology , Middle Aged , Phylogeny , Young AdultSubject(s)
Disease Outbreaks , Influenza A Virus, H1N1 Subtype/isolation & purification , Influenza, Human/epidemiology , Influenza, Human/virology , Adolescent , Adult , Age Distribution , Aged , Child , Child, Preschool , Europe/epidemiology , Female , Humans , Infant , Influenza A Virus, H1N1 Subtype/classification , Male , Middle Aged , Population Surveillance , Prevalence , Seasons , Seroepidemiologic Studies , Young AdultSubject(s)
Communicable Diseases, Emerging/diagnosis , Influenza A Virus, H7N9 Subtype/genetics , Influenza A Virus, H7N9 Subtype/isolation & purification , Influenza in Birds/virology , Laboratories , Animals , Birds , Europe , Health Surveys , Humans , Influenza in Birds/diagnosis , Influenza, Human/diagnosis , Influenza, Human/virology , Risk Assessment , Sequence Analysis, RNA , Surveys and QuestionnairesABSTRACT
OBJECTIVES: Hospital-based surveillance of influenza and acute respiratory infections relies on International Classification of Diseases (ICD) codes and hospital laboratory reports (Standard-of-Care). It is unclear how many cases are missed with either method, i.e. remain undiagnosed/coded as influenza and other respiratory virus infections. Various influenza-like illness (ILI) definitions co-exist with little guidance on how to use them. We compared the diagnostic accuracy of standard surveillance methods with a prospective quality management (QM) programme at a Berlin children's hospital with the Robert Koch Institute. METHODS: Independent from routine care, all patients fulfilling pre-defined ILI-criteria (QM-ILI) participated in the QM programme. A separate QM team conducted standardized clinical assessments and collected nasopharyngeal specimens for blinded real-time quantitative PCR for influenza A/B viruses, respiratory syncytial virus, adenovirus, rhinovirus and human metapneumovirus. RESULTS: Among 6073 individuals with ILI qualifying for the QM programme, only 8.7% (528/6073) would have undergone virus diagnostics during Standard-of-Care. Surveillance based on ICD codes would have missed 61% (359/587) of influenza diagnoses. Of baseline ICD codes, 53.2% (2811/5282) were non-specific, most commonly J06 ('acute upper respiratory infection'). Comparison of stakeholder case definitions revealed that QM-ILI and the WHO ILI case definition showed the highest overall sensitivities (84%-97% and 45%-68%, respectively) and the CDC ILI definition had the highest sensitivity for influenza infections (36%, 95% CI 31.4-40.8 for influenza A and 48%, 95% CI 40.5-54.7 for influenza B). CONCLUSIONS: Disease-burden estimates and surveillance should account for the underreporting of cases in routine care. Future studies should explore the effect of ILI screening and surveillance in various age groups and settings. Diagnostic algorithms should be based on the WHO ILI case definition combined with targeted testing.
Subject(s)
Quality Assurance, Health Care/statistics & numerical data , Respiratory Tract Infections/diagnosis , Standard of Care/statistics & numerical data , Virus Diseases/diagnosis , Viruses/isolation & purification , Adolescent , Child , Child, Preschool , Female , Hospitals , Humans , Infant , Infant, Newborn , Influenza, Human/classification , Influenza, Human/diagnosis , International Classification of Diseases/standards , Male , Nasopharynx/virology , Population Surveillance , Prospective Studies , Quality Assurance, Health Care/standards , Real-Time Polymerase Chain Reaction , Respiratory Tract Infections/classification , Respiratory Tract Infections/virology , Standard of Care/standards , Virus Diseases/classificationSubject(s)
Disease Notification/statistics & numerical data , Influenza A Virus, H1N1 Subtype/isolation & purification , Influenza, Human/epidemiology , Pandemics , Europe/epidemiology , European Union/statistics & numerical data , Humans , Incidence , Influenza, Human/diagnosis , Influenza, Human/virology , Population Surveillance , Risk Factors , Severity of Illness IndexABSTRACT
The Us3 kinase is part of the antiapoptotic arsenal that salvages herpes simplex virus (HSV)-1-infected cells from damage caused by different stimuli. We demonstrate that Us3 protects HSV-1-infected cells from lysis by MHC class I-restricted CD8T cells without affecting antigen presentation. Expression of Us3 was associated with inhibition of caspase activation and reduced cleavage of the proapoptotic protein Bid. Recombinant granzyme B (GrB) failed to cleave Bid in cytosolic extracts from Us3 positive cells, while recombinant Bid served as substrate for Us3 phosphorylation, suggesting that modification of Bid by Us3 blocks its processing by GrB. Our data illustrate a new strategy of viral escape, where modification of a cellular proapoptotic substrate may prevent lysis of the infected cells without affecting other T-cell functions.
Subject(s)
CD8-Positive T-Lymphocytes/metabolism , Carrier Proteins/metabolism , Protein Serine-Threonine Kinases/physiology , Serine Endopeptidases/pharmacology , Antigen Presentation , Apoptosis , BH3 Interacting Domain Death Agonist Protein , Blotting, Western , Caspases/metabolism , Cell Line , Cytosol/metabolism , Dose-Response Relationship, Drug , Enzyme Activation , Granzymes , Humans , Lymphocytes/metabolism , Major Histocompatibility Complex , Microscopy, Fluorescence , Mutation , Phosphorylation , Protein Binding , Protein Serine-Threonine Kinases/metabolism , Recombinant Proteins/chemistry , Recombinant Proteins/metabolism , T-Lymphocytes, Cytotoxic/metabolism , Tumor Necrosis Factor-alpha/metabolism , Viral ProteinsABSTRACT
Linomide (quinoline-3-carboxamide) is an immunomodulator with diverse effects on the immune system. Its beneficial effects on experimental autoimmune disease models have been linked to downregulation of Th1 cytokines and altered macrophage functions. We studied this effect of downregulation of Th1-type of immune response on Semliki Forest A7 virus infection in experimental autoimmune encephalomyelitis (EAE) susceptible Th1-prone SJL mice and in EAE-resistant Th2-prone BALB/c mice. We aimed at addressing the target-cell population of Linomide responsible for this Th1 downregulation. Treatment with Linomide led to increased virus infection in brain and this effect coincided with decreased production of IL-12 and IFN-gamma from stimulated spleen cells in SJL mice. In contrast, IL-12 and IFN-gamma expression were increased in Linomide-treated BALB/c mice. Treatment of infected SJL mice resulted in decreased percentage of CD11b+ and CD11c+ cells. Thus, the target cell population of Linomide may be antigen-presenting cells (APC) which are considered as candidates for regulatory cells of Th1/Th2 balance.
Subject(s)
Adjuvants, Immunologic/pharmacology , Alphavirus Infections/immunology , Hydroxyquinolines/pharmacology , Th1 Cells/immunology , Th2 Cells/immunology , Animals , Antigen-Presenting Cells/drug effects , Brain/virology , CD11b Antigen/analysis , Encephalomyelitis, Autoimmune, Experimental/immunology , Interferon-gamma/biosynthesis , Interleukin-12/biosynthesis , Mice , Mice, Inbred BALB C , RNA, Viral/analysis , Semliki forest virus , Spleen/cytology , Viral LoadABSTRACT
BACKGROUND: The first antiviral susceptibility testing external quality assessment (EQA) was held for European influenza reference laboratories during winter 2010/11. OBJECTIVES: To assess European network influenza antiviral susceptibility testing capability and provide participants with an independent performance evaluation. STUDY DESIGN: The EQA panel contained ten coded specimens of inactivated human influenza A and B viruses with reduced susceptibility to neuraminidase inhibitors (NAI), or adamantanes. Twenty-four laboratories from 19 member states of the WHO European region analysed the panel using phenotypic (determination of 50% inhibitory concentration (IC(50)) values by neuraminidase (NA) enzyme inhibition assay) and/or genotypic methods. RESULTS: All 24 laboratories returned genotypic data for A(H1N1)pdm09 influenza virus, 18 (75%) for former seasonal A(H1N1), 16 (67%) for A(H3N2) and 15 (63%) for influenza B virus, correctly identifying NAI or adamantane reduced susceptibility-associated substitutions in the NA (mean 84%; range 52-100%) or M2 (mean 85%; range 73-94%), respectively. Thirteen laboratories (54%) returned phenotypic NAI susceptibility data. Despite inter-laboratory and inter-assay IC(50) value variation, all 13 laboratories correctly identified oseltamivir reduced susceptibility/resistance in pure preparations of A(H1N1) oseltamivir-resistant viruses. However, only 11 (85%) identified oseltamivir reduced susceptibility/resistance in a mixture of A(H1N1)pdm09 oseltamivir-sensitive/-resistant viruses. Furthermore, 3 laboratories (23%) considered oseltamivir-sensitive influenza B virus reduced susceptible/resistant. CONCLUSIONS: Detection of NA-H275Y in A(H1N1) viruses was achieved by most laboratories. IC(50) values and interpretation thereof varied for a sensitive/resistant virus mixture and for influenza B virus. The results of this exercise will assist harmonisation of antiviral susceptibility testing, interpretation and reporting within the European network through targeted training.
Subject(s)
Antiviral Agents/pharmacology , Influenza A virus/drug effects , Influenza B virus/drug effects , Laboratory Proficiency Testing , Microbial Sensitivity Tests/standards , Europe , Genotype , Influenza A virus/genetics , Influenza B virus/genetics , Inhibitory Concentration 50 , Mutation, MissenseABSTRACT
Health hazards related to unsuitable ergonomic work conditions among female employees in Sweden are reviewed. The statistics on reported occupational strain injuries form an important source of information on prevention. The report rate is higher among men than among women, but in some high risk occupations the figures are similar. Reported cases concerning neck, arm and shoulder disorders constitute a larger proportion among women. This finding probably reflects differences in work load characteristics, women more often performing repetitive monotonous work tasks in the manufacturing industry. Serious ergonomic problems exist for women in the service sector although the statistical evidence for increased morbidity is not yet available.
Subject(s)
Accidents, Occupational/statistics & numerical data , Occupational Diseases/etiology , Wounds and Injuries/etiology , Accidents, Occupational/prevention & control , Female , Humans , Occupational Diseases/prevention & control , Risk Factors , Sweden , Wounds and Injuries/prevention & controlABSTRACT
We have used interleukin (IL)-4 and -10-producing HSV-1 gamma(1)34.5 deletion viruses in gene therapy of a BALB/c model of experimental allergic encephalomyelitis (EAE), a T cell-mediated demyelinating disease of the central nervous system. It is known that in EAE of mice the Th2-type cytokines are down-regulated and the Th1-type cytokines up-regulated during the onset and relapse of the disease. Therefore, we tested two HSV-1 recombinants expressing the Th2-type cytokines IL-4 and IL-10. The recombinant viruses were injected intracranially (i.c.) in BALB/c mice 6 days after induction of EAE. As control groups we used mice without any infection, mice infected with backbone virus R3659 and mock-infected mice. Weights and symptoms of the mice were recorded daily and the tissue specimens were collected at specific time-points. The results indicate that the intracranial infection with IL-4-producing virus (1) precludes EAE symptoms, (2) protects the spinal cord from massive leukocyte infiltrations and (3) prevents demyelination and axonal loss. The IL-10-expressing virus R8308 did not have a similar favorable effect on the recovery of the mice as did the IL-4 virus R8306.
Subject(s)
Encephalomyelitis, Autoimmune, Experimental/prevention & control , Genetic Therapy/methods , Genetic Vectors/administration & dosage , Herpesvirus 1, Human/genetics , Interleukin-10/genetics , Interleukin-4/genetics , Animals , Brain/virology , Female , Gene Expression , Immunohistochemistry , Mice , Mice, Inbred BALB C , Spinal Cord/virology , Statistics, NonparametricABSTRACT
Herpes simplex virus (HSV) is a common neurotropic virus which infects epithelial cells and subsequently the trigeminal ganglia (TG) and brain tissue. We studied how immunomodulation with roquinimex (Linomide) affects the course of corneal HSV infection in BALB/c mice. BALB/c mice have also been used in a model for HSV-based vectors in treating an autoimmune disease of the central nervous system (CNS). We addressed the questions of how immunomodulation affects the local as well as the systemic immune response and whether roquinimex could facilitate the spread of HSV to the CNS. The cytokine response in the brain and TG was studied using a quantitative rapid real-time RT-PCR method. We were interested in whether immunomodulation affects the expression of the recently described Th1-cytokine IL-23p19 in the brain and TG. The expression of IL-23 mRNA was decreased in brains of roquinimex-treated BALB/c mice. Also the expression of IL-12p35 and IFN-gamma mRNAs decreased. No significant changes were seen in IL-4 and IL-10 mRNA expression. The cytokine response was also studied using supernatants of stimulated splenocytes by EIA. Roquinimex treatment suppressed the production of IFN-gamma and also the production of IL-10 in HSV-infected BALB/c mice.